Clinical trial
A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease
NCT00199394 · Kyowa Kirin Co., Ltd., Industry · Completed
Key facts
| NCT number | NCT00199394 |
|---|---|
| Title | A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease |
| Official title | A 16-week, Double-Blind, Placebo-Controlled, Randomised, Parallel-Group, Multicentre, International Study to Evaluate the Efficacy and Safety of 40 mg/Day KW-6002 (Istradefylline) and That of Entacapone Versus Placebo as Treatment for Parkinson's Disease in Patients With Motor Response Complications… |
| Lead sponsor | Kyowa Kirin Co., Ltd., Industry |
| Collaborators | Kyowa Hakko Kirin UK, Ltd. Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Parkinson's Disease |
| Intervention type | Drug |
| Interventions | Istradefylline (KW-6002) |
| Enrollment | 405 |
| Start date | Nov 1, 2004 |
| Primary completion | Oct 1, 2005 |
| Completion | Nov 1, 2005 |
| First posted | Sep 20, 2005 |
| Last update posted | Apr 25, 2024 |
| Countries | United Kingdom |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: